Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Master Protocol of FORE8394 in cancers with BRAF alterations
2022-000627-20Phase 2Active
- Sponsor
- Fore Biotherapeutics
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of plixorafenib in cancer and Neoplasm, sponsored by Fore Biotherapeutics. Primary endpoint: Primary Endpoint for Subprotocol A. Started Sep 2022; status: active.
02
Drugs
plixorafenib
03
Conditions
cancerNeoplasm
Beyond the preview
Go deeper on 2022-000627-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000627-20.